Boston Scientific Corp. vs. Stryker Corporation
Boston Scientific Corp. and Stryker Corporation are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BSX | SYK | |
|---|---|---|
| Market Cap | $70.19 billion | $130.88 billion |
| Revenue (TTM) | — | $25.84 billion |
| Net Income (TTM) | — | $3.73 billion |
SYK leads on 1 of 1 size & scale factors.
Valuation
| BSX | SYK | |
|---|---|---|
| P/E Ratio | — | 34.81 |
| Price / Book | — | 5.46 |
| Price / Sales | — | 5.07 |
BSX and SYK split the valuation factors evenly.
Profitability
| BSX | SYK | |
|---|---|---|
| Net Margin | — | 14.43% |
| Return on Equity | — | 15.55% |
BSX and SYK split the profitability factors evenly.
Dividend
| BSX | SYK | |
|---|---|---|
| Dividend Yield | — | 1.05% |
| Payout Ratio | — | 36.48 |
BSX and SYK split the dividend factors evenly.
Risk & Sentiment
| BSX | SYK | |
|---|---|---|
| Short Interest | 0.70% | 1.53% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, SYK overview, SYK financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.